ESR1 and breast carcinoma: These cell lines are considered relevant experimental models since TAM acts as a growth antagonist in MCF7 but shows little growth inhibiting activity against BT474 and can actually stimulate growth of MCF7/HER2 [18], similar to clinical observations with TAM treated ER-positive/ErbB2-positive breast cancers [33].